|Bid||108.86 x 900|
|Ask||109.84 x 900|
|Day's range||108.79 - 110.93|
|52-week range||101.24 - 142.60|
|Beta (5Y monthly)||0.70|
|PE ratio (TTM)||22.96|
|Forward dividend & yield||1.88 (1.70%)|
|Ex-dividend date||14 Jul 2022|
|1y target est||N/A|
Today's Research Daily features new research reports on 12 major stocks, including JPMorgan Chase & Co. (JPM), AbbVie Inc. (ABBV) and Abbott Laboratories (ABT).
Thermo Fisher's (TMO) novel Applied Biosystems HIV-1 Genotyping Kit will aid in the global efforts to monitor the evolution of HIV.
With 50 consecutive years of dividend growth, healthcare giant Abbott Laboratories (NYSE: ABT) is a Dividend King. In late July, Abbott Laboratories shared its financial results for the second quarter ended June 30. As was also the case in the previous quarter, Abbott's nutrition segment was the only segment to not log year-over-year sales growth.